60 related articles for article (PubMed ID: 38078486)
1. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Gill SI; Lai C; Porter DL; Skuli S; Bruno XJ; Carroll MP; Freyer CW; Carulli A; Babushok DV; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Loren AW; Paralkar VR; Maillard IP; Pratz KW
Am J Hematol; 2023 Aug; 98(8):1254-1264. PubMed ID: 37334852
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
Liang P; Xie Y; Liu Z; Wang D; Li Q; Lu Y; Xue S; Wang Y; Chen S; Wu D; Fu J
Br J Haematol; 2024 Apr; 204(4):1219-1226. PubMed ID: 38180132
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
[TBL] [Abstract][Full Text] [Related]
7.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.
Park S; Kim TY; Cho BS; Kwag D; Lee JM; Kim M; Kim Y; Koo J; Raman A; Kim TK; Kim HJ
Haematologica; 2024 Apr; 109(4):1095-1106. PubMed ID: 37706344
[TBL] [Abstract][Full Text] [Related]
9. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia.
Jin D; Chen H; He J; Li Y; Zheng G; Yang Y; Zhao Y; Le J; Shu W; He D; Cai Z
Target Oncol; 2024 Mar; 19(2):237-249. PubMed ID: 38466536
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
[TBL] [Abstract][Full Text] [Related]
12. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
Shimony S; Garcia JS; Keating J; Chen EC; Luskin MR; Stahl M; Neuberg DS; DeAngelo DJ; Stone RM; Lindsley RC
Leukemia; 2024 Mar; ():. PubMed ID: 38538860
[TBL] [Abstract][Full Text] [Related]
13. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E; Cohen I; Amitai I; Ram R; Frisch A; Nachmias B; Canaani J; Moshe Y; Krayem B; Aumann S; Henig I; Vainstein V; Shargian L; Ganzel C; Yeshurun M; Levi I; Raanani P; Akria L; Ofran Y; Shimony S; Wolach O
Br J Haematol; 2024 May; ():. PubMed ID: 38782575
[TBL] [Abstract][Full Text] [Related]
14. A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients.
Zhang L; Ge R; Pan D; Yue P; Zhang J; Bian R; Yan X
Front Pharmacol; 2024; 15():1265840. PubMed ID: 38756378
[TBL] [Abstract][Full Text] [Related]
15. Advancements and Challenges in the Treatment of AML.
Abaza Y; McMahon C; Garcia JS
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e438662. PubMed ID: 38662975
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].
Liu L; He F; Xu Y; Li T; Li YF; Tang P; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):277-283. PubMed ID: 38716600
[No Abstract] [Full Text] [Related]
17. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Roboz GJ; Sanz G; Griffiths EA; Yee K; Kantarjian H; Récher C; Byrne MT; Patkowska E; Kim HJ; Thomas X; Moors I; Stock W; Illés Á; Fenaux P; Miyazaki Y; Yamauchi T; O'Connell CL; Hao Y; Keer HN; Azab M; Döhner H
Blood Adv; 2024 Apr; 8(8):2020-2029. PubMed ID: 38231126
[TBL] [Abstract][Full Text] [Related]
18. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
Ravindran M; Mozessohn L; Cheung M; Buckstein R; Teichman J
Blood Adv; 2024 Feb; 8(3):629-639. PubMed ID: 38029373
[TBL] [Abstract][Full Text] [Related]
19. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Senapati J; Kantarjian HM; Bazinet A; Reville P; Short NJ; Daver N; Borthakur G; Bataller A; Jabbour E; DiNardo C; Haddad F; Sasaki K; Popat U; Oran B; Alousi AM; Loghavi S; Shpall E; Garcia-Manero G; Ravandi F; Kadia TM
Cancer; 2024 May; ():. PubMed ID: 38809547
[TBL] [Abstract][Full Text] [Related]
20. Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
Chen EC; Garcia JS
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):41-50. PubMed ID: 33275683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
